MedTrace Logo

Drug Interaction Study of MGL-3196 With Atorvastatin

NCT02749578 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2016-08-30

No results posted yet for this study

Summary

The purpose of this study is to determine whether MGL-3196 alters the pharmacokinetics of atorvastatin in healthy male subjects and female subjects not of child-bearing potential.

Conditions

  • Healthy

Interventions

DRUG

Atorvastatin

DRUG

MGL-3196

Sponsors & Collaborators

  • Celerion

    collaborator INDUSTRY

  • Madrigal Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Danielle Armas, MD · Celerion

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02749578 on ClinicalTrials.gov